Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

179 results
Display

Soluble CD40 Levels in Plasma Are Associated with Cardiovascular Disease and in Carotid Plaques with a Vulnerable Phenotype

Shami A, Edsfeldt A, Bengtsson E, Nilsson J, Shore AC, Natali A, Khan F, Lutgens E, Gonçalves I

Background and Purpose CD40 and CD40 ligand (CD40L) are costimulatory molecules of the tumor necrosis factor receptor superfamily and well known for their involvement in inflammatory diseases: atherosclerotic mouse models...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors

Song DW, Ro WB, Park HM

Background Programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have important roles in tumor evasion of the immune system. Objectives This study aimed to assess the diagnostic utility of circulating...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Programmed Cell Death-Ligand 1 (PD-L1) gene Single Nucleotide Polymorphism in Graves’ Disease and Hashimoto’s Thyroiditis in Korean Patients

Yoon JH, Shin Mh, Kim HN, Choi W, Park JY, Hong AR, Kim HK, Kang HC

Background: Programmed cell death-ligand 1 (PD-L1) has an important role in regulating immune reactions by binding to programmed death 1 (PD-1) on immune cells, which could prevent the exacerbation of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation

Lee KS, Choe G

Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibition has revolutionized the treatment paradigm of urothelial carcinoma (UC). Several PD-L1 assays are conducted to formulate appropriate treatment decisions for PD-1/PD-L1...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Impact of Natural Killer Group 2D Receptor Expression and That of Its Ligand in Ovarian Carcinomas: A Retrospective Study

Lee GH, An HJ, Kim TH, Kim G, Park KS, Park H, Lee TH, Kwon AY

Purpose: Natural killer (NK) cells are innate immune cells with antitumor activity. NKG2D is the most important activating receptor expressed on the NK cell surface; this receptor binds to the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tocotrienol regulates osteoclastogenesis in rheumatoid arthritis

Kim KW, Kim BM, Won JY, Min HK, Lee SJ, Lee SH, Kim HR

Background/Aims: The present study aimed to investigate whether tocotrienol regulates interleukin 17 (IL-17)-induced osteoclastogenesis in rheumatoid arthritis (RA). Methods: We evaluated the effect of tocotrienol on IL-17-induced receptor activator of nuclear...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
TL1A/TNFR2 Axis Enhances Immunoregulatory Effects of Bone Marrow Derived Mesenchymal Stem Cell by Indian Hedgehog Signaling Pathway

Al-Azab M, Walana W, Wei J, Li W, Tang Y, Wei X, Almoiliqy M, Shopit A, Abbas EE, Adlat S, Awsh M, Li X, Wang B

Background and Objectives: The immunomodulatory potential of mesenchymal stem cells (MSCs) can be regulated by a variety of molecules, especially cytokines. The inflammatory cytokine, TNF-like ligand 1A (TL1A), has been...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Characterization of Congo red binding in Streptococcus gordonii

Kim EJ, Lee SY

Iron is essential for bacterial growth. The ability to use heme compounds to derive iron in pathogenic bacteria has been reported. In some pathogenic bacteria, studies indicated that hemin binding...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Changes in Serum Dickkopf-1, RANK Ligand, Osteoprotegerin, and Bone Mineral Density after Allogeneic Hematopoietic Stem Cell Transplantation Treatment

Jang E, Ha J, Baek KH, Kang MI

Background: Dickkopf-1 (DKK1) regulates bone formation by inhibiting canonical Wnt/β-catenin pathway signaling, and indirectly enhances osteoclastic activity by altering the expression ratio of receptor activator of nuclear factor-κB ligand (RANKL)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas

Samman DME, Mahdy MME, Cousha HS, Kamar ZAER, Mohamed KAK, Gabal HHA

Background: Glioblastoma is the most aggressive primary malignant brain tumor in adults and is characterized by poor prognosis. Immune evasion occurs via programmed death-ligand 1 (PD-L1)/programmed death receptor 1 (PD-1)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Denosumab (RANKL Inhibitor): A Potent Anti-Resorptive Agent

Byun SE

Denosumab, a fully human monoclonal antibody to the receptor activator of nuclear factor-kappa B ligand, was introduced and used as an anti-osteoporotic agent. Denosumab prevents bone resorption by inhibiting the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
An update on immunotherapy with PD-1 and PD-L1 blockade

Koh SA

Cancer is the leading cause of death and is on the rise worldwide. Until 2010, the development of targeted treatment was mainly focused on the growth mechanisms of cancer. Since...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Exploring the mythical abscopal effect: Radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma

Kim JW, Lee IJ

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity

Lee SE, Shin AR, Sohn HJ, Cho HI, Kim TG

Purpose Successful tumor eradication primarily depends on generation and maintenance of a large population of tumor-reactive CD8 T cells. Dendritic cells (DCs) are well-known potent antigen-presenting cells and have applied to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs

Park Y, Koh J, Na HY, Kwak Y, Lee KW, Ahn SH, Park DJ, Kim HH, Lee HS

Purpose We provide a comparison between 22C3 pharmDx and SP263 assay, for evaluating programmed death ligand 1 (PD-L1) expression in advanced gastric cancer (GC) patients. Materials and Methods The PD-L1 immunohistochemistry...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Anti-programmed Cell Death Ligand 1 and Anti-transforming Growth Factor Beta Antibody-associated Keratoacanthoma

Byun HJ, Choi Y, Park CS, Lim Y, Park S, Lee DY, Park JH

  • KMID: 2502808
  • Korean J Dermatol.
  • 2020 Mar;58(3):204-206.
Keratoacanthomas (KAs) are epithelial skin tumors characterized by rapid growth and spontaneous regression, with histopathologic features similar to those of cutaneous squamous cell carcinoma (SCC). KA arising after the use...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer

Kim JH, Kim K, Kim M, Kim YM, Suh JH, Cha HJ, Choi HJ

Background: Immunomodulatory therapies targeting the interaction between programmed cell death protein 1 and programmed death-ligand 1 (PD-L1) have become increasingly important in anticancer treatment. Previous research on the subject of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy

Kim KH, Kim CG, Shin EC

Immune checkpoint blockade targeting PD-1 and PD-L1 has resulted in unprecedented clinical benefit for cancer patients. Anti-PD-1/PD-L1 therapy has become the standard treatment for diverse cancer types as monotherapy or...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tumor immune response and immunotherapy in gastric cancer

Kwak Y, Seo AN, Lee HE, Lee HS

Remarkable developments in immuno-oncology have changed the landscape of gastric cancer (GC) treatment. Because immunotherapy intervenes with tumor immune response rather than directly targeting tumor cells, it is important to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation

Yoon S, Eom GH

Cancer remains a leading cause of death, despite multimodal treatment approaches. Even in patients with a healthy immune response, cancer cells can escape the immune system during tumorigenesis. Cancer cells...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr